Clinical Trial Update: Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of an anti-CD40L monoclonal antibody in combination with transplanted islet cells f…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• CD40L monoclonal antibody

Snippet

Sponsor: University of Chicago | Conditions: Type 1 Diabetes Mellitus | Phase 1, Phase 2 | Status: RECRUITING